A Phase 2 Trial of Nivolumab Plus Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer

Trial Profile

A Phase 2 Trial of Nivolumab Plus Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Jun 2017

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms CheckMate 650
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 19 Apr 2017 Planned primary completion date changed from 1 Jul 2018 to 16 Dec 2018.
    • 21 Mar 2017 Status changed from not yet recruiting to recruiting.
    • 07 Mar 2017 Planned End Date changed from 1 Feb 2022 to 1 Mar 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top